Roivant Sciences (NASDAQ:ROIV) PT Raised to $14.00 at JPMorgan Chase & Co.

Roivant Sciences (NASDAQ:ROIV – Get Rating) had its target price hoisted by equities research analysts at JPMorgan Chase & Co. from $12.00 to $14.00 in a report issued on Thursday, The Fly reports. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 50.21% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. HC Wainwright upped their price objective on shares of Roivant Sciences from $14.00 to $15.00 in a research note on Wednesday. The Goldman Sachs Group upped their target price on shares of Roivant Sciences from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, January 19th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Roivant Sciences currently has a consensus rating of “Buy” and a consensus price target of $12.80.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $9.32 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.74 and a quick ratio of 6.74. Roivant Sciences has a 1 year low of $2.87 and a 1 year high of $10.00. The company has a market capitalization of $7.07 billion, a PE ratio of -5.24 and a beta of 1.22. The company has a fifty day moving average of $8.20 and a two-hundred day moving average of $7.64.

Insider Buying and Selling

In related news, COO Eric Venker sold 61,206 shares of the stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $8.93, for a total transaction of $546,569.58. Following the completion of the transaction, the chief operating officer now directly owns 675,768 shares of the company’s stock, valued at $6,034,608.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Eric Venker sold 61,206 shares of the stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $8.93, for a total transaction of $546,569.58. Following the completion of the transaction, the chief operating officer now directly owns 675,768 shares of the company’s stock, valued at $6,034,608.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vivek Ramaswamy sold 4,000,000 shares of the stock in a transaction dated Wednesday, February 22nd. The stock was sold at an average price of $7.95, for a total transaction of $31,800,000.00. Following the transaction, the director now directly owns 54,409,211 shares of the company’s stock, valued at $432,553,227.45. The disclosure for this sale can be found here. Insiders sold 16,509,880 shares of company stock valued at $132,131,966 over the last ninety days. Corporate insiders own 13.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Citigroup Inc. grew its position in Roivant Sciences by 1,803.6% during the first quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock worth $28,000 after buying an additional 5,447 shares during the period. Royal Bank of Canada grew its position in shares of Roivant Sciences by 60,550.0% in the first quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock valued at $30,000 after purchasing an additional 6,055 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Roivant Sciences during the third quarter worth approximately $35,000. Jane Street Group LLC purchased a new position in Roivant Sciences during the third quarter worth approximately $48,000. Finally, BNP Paribas Arbitrage SNC purchased a new position in Roivant Sciences during the third quarter worth approximately $49,000. 52.66% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.